Outcomes	Rosuvastatin (n = 155)	Control (n = 157)	P value
Thrombotic events, n (%)
Recurrent major VTE (total)	3 (1.9)	2 (1.3)	0.68
Recurrent DVT	1 (0.6)	0	0.50
Recurrent PE	2 (1.3)	2 (1.3)	1
Recurrent non‐major VTE	1 (0.6)	0	0.50
Arterial events (total)	1 (0.6)	0	0.50
Myocardial infarction	0	0	1
Stroke/TIA	1 (0.6)	0	0.50
Acute limb ischemia	0	0	1
Death from any cause, n (%)	0	1 (0.6)	1
Major bleed, n (%)	0	1 (0.6)	1
Clinically relevant nonmajor bleeding, n (%)	2 (1.3)	1 (0.6)	1
Major muscle toxicity (CK>10ULN), n (%)	1 (0.6)	0	1
Muscle‐related adverse events, n (%)	11 (7.1)	1 (0.6)	0.01